Home Antibody All anti-TNFRSF25 antibodies
Also for TNFRSF25 (NM_001039664)
|DR3 antibody was raised against a peptide corresponding to amino acids in extracellular domain (ED) of human DR3 precusor.|
||0.5~1.0 mg/ml (Lot Dependent)
||ELISA, WB: 1 ug/ml, ICC: 10 ug/ml, IF: 20 ug/ml
|PBS containing 0.02% sodium azide.|
|Antibody is DEAE purified
|Homo sapiens tumor necrosis factor receptor superfamily, member 25 (TNFRSF25), transcript variant 12|
|APO-3; DDR3; DR3; LARD; TNFRSF12; TR3; TRAMP; WSL-1; WSL-LR|
|Apoptosis, or programmed cell death, occurs during normal cellular differentiation and development of multicellular organisms. Apoptosis is induced by certain cytokines including TNF and Fas ligand of the TNF family through their death domain containing receptors, TNFR1 and Fas. A novel cell death receptor was recently identified by several groups independently and designated DR3, Wsl-1, Apo-3, TRAMP and LARD1-5. The ligand for this novel death receptor has been defined as TWEAK, also termed Apo3L. DR3 is highly expressed in the tissues enriched in lymphocytes including PBL, thymus and spleen. Like TNFR1, DR3 induces apoptosis and NF-kappaB activation.|
Cytokine-cytokine receptor interaction
* Shipping is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
Western blot analysis of DR3 in Jurkat total cell lysate with DR3 antibody at 1:1000 dilution.
Immunocytochemistry of DR3 in Jurkat cells with DR3 antibody at 10 ug/mL.